Company / EPS (Diluted)
Actinium Pharmaceuticals, Inc. EPS (Diluted) History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.27
FY2025
5-year range
-$1.83 / -$1.20
FY2021-FY2025
Trend
+30.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-1.27.
Based on SEC 10-K filings.
-1.27 in FY2025.
Improved from $-1.37 to $-1.27 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 30.6% year-over-year.
- Peak eps (diluted) was recorded in FY2011.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.27 | +30.6% |
| FY2024 | -$1.83 | -33.6% |
| FY2023 | -$1.37 | -14.2% |
| FY2022 | -$1.20 | +34.4% |
| FY2021 | -$1.83 | -18400.0% |
| FY2011 | $0.01 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026